Meeting
2017 ASCO Annual Meeting
The role of high-dose chemotherapy (CT) and stem-cell support in high-risk stage II, locally advanced, and responding stage IV breast cancer (BC): The Israeli experience with 20 years median follow-up.
Authors
Idit Peretz
Rabin Medical Center, Petah Tikva, Israel
Idit Peretz , Shulamith Rizel , Izhar Hardan , Salomon M. Stemmer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1077)
DOI
10.1200/JCO.2017.35.15_suppl.1077
Abstract #
1077
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer.
First Author: A. M. Vanderwalde
Poster
2014 ASCO Annual Meeting
BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.
First Author: Philip C. Schouten
Poster
2013 ASCO Annual Meeting
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.
First Author: Philip C. Schouten
Poster
2012 Breast Cancer Symposium
Chemotherapy treatment patterns for early-stage breast cancer (ESBC): Decreasing use of anthracycline-based regimens.
First Author: Katherine Serrurier